Pieris Pharmaceuticals (NASDAQ:PIRS) Raised to Hold at StockNews.com

Pieris Pharmaceuticals (NASDAQ:PIRS) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

Pieris Pharmaceuticals Stock Up 1.0 %

Shares of PIRS stock traded up $0.15 during trading hours on Tuesday, reaching $15.59. 46,391 shares of the stock traded hands, compared to its average volume of 47,970. The business has a fifty day moving average price of $16.57 and a 200 day moving average price of $13.83. Pieris Pharmaceuticals has a 1-year low of $6.20 and a 1-year high of $22.32. The firm has a market capitalization of $20.58 million, a PE ratio of -1.29 and a beta of 0.66.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Pieris Pharmaceuticals stock. Frazier Life Sciences Management L.P. bought a new stake in shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 15,942 shares of the biotechnology company’s stock, valued at approximately $267,000. Frazier Life Sciences Management L.P. owned approximately 1.21% of Pieris Pharmaceuticals at the end of the most recent reporting period. 40.11% of the stock is currently owned by institutional investors and hedge funds.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.